A A Adjei


Affiliation: Mayo Clinic
Country: USA


  1. Anwar S, Tan W, Hong C, Admane S, Dozier A, Siedlecki F, et al. Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events. Cancers (Basel). 2017;9: pubmed publisher
    ..04). Conclusions: Lower (worse) EORTC QLQ-C30 score at baseline is associated with SAE occurrence during phase 1 oncology trials. ..
  2. Xie H, Adjei A. Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. J Thorac Oncol. 2018;: pubmed publisher
    ..We then discuss antibody-drug conjugates currently in clinical development for thoracic malignancies. ..
  3. Wang F, Molina J, Satele D, Yin J, Lim V, Adjei A. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. Invest New Drugs. 2018;: pubmed publisher
    ..This combination should not be developed further unless predictive biomarkers can be identified. ..
  4. Jazieh K, Molina J, Allred J, Yin J, Reid J, Goetz M, et al. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Invest New Drugs. 2018;: pubmed publisher
    ..Tipifarnib is currently being evaluated in HRAS mutant tumors, providing a potential opportunity to further test this combination. ..
  5. Adjei A. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003;3:145-56 pubmed
    ..More importantly, vitamin supplementation has not demonstrated any adverse efficacy. This review discusses the biochemistry and clinical activity of pemetrexed. ..
  6. Adjei A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004;10:4276s-4280s pubmed
    ..Low level dietary supplement of folic acid and vitamin B12 has significantly decreased the mucosal and bone marrow toxicity of pemetrexed without compromising its antitumor effect. ..
  7. Adjei A, Davis J, Erlichman C, Svingen P, Kaufmann S. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000;6:2318-25 pubmed
    ..Our results indicate that unprocessed HDJ-2 and prelamin A should be suitable markers of FT inhibition in clinical samples. ..
  8. Adjei A. Current data with pemetrexed (Alimta) in non-small-cell lung cancer. Clin Lung Cancer. 2003;4 Suppl 2:S64-7 pubmed
    ..Approval for pemetrexed in combination with cisplatin in advanced mesothelioma is expected within the next 12 months. This review discusses the activity of pemetrexed in NSCLC...
  9. Soria J, Adjei A, Bahleda R, Besse B, Ferte C, Planchard D, et al. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced . Eur J Cancer. 2017;86:186-196 pubmed publisher
    ..9%) patients. Combining pictilisib with various standard-of-care first-line treatment regimens is feasible from a safety perspective in patients with NSCLC, and encouraging preliminary anti-tumour activity was observed. ..

More Information


  1. Adjei A, Reid J, Erlichman C, Sloan J, Pitot H, Alberts S, et al. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs. 2002;20:297-304 pubmed
    ..Subsequent studies revealed that PZA inhibits removal of platinum-DNA adducts in cultured A549 cells. Based on these results, we undertook a phase I study of the combination of PZA and carboplatin (CBDCA)...
  2. Adjei A, Croghan G, Erlichman C, Marks R, Reid J, Sloan J, et al. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003;9:2520-6 pubmed
    ..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...
  3. Adjei A. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004;5 Suppl 2:S51-5 pubmed
    ..Tumors with codeletion of the methylthioadenosine phosphorylase gene, as a consequence of p16 deletions, may be particularly sensitive to pemetrexed. In this review, the biochemistry and mechanism of action of pemetrexed are discussed...
  4. Adjei A. Targeting multiple signal transduction pathways in lung cancer. Clin Lung Cancer. 2005;7 Suppl 1:S39-44 pubmed
    ..These inhibitors include ZD6474, SU11248, AEE 788, sorafenib, vatalanib, and AG-013736...
  5. Adjei A. Sequencing bortezomib with chemotherapy and targeted agents. Clin Lung Cancer. 2005;7 Suppl 2:S56-8 pubmed
    ..This review provides an overview of selected interactions between bortezomib and other anticancer agents preclinically and in early clinical trials...
  6. Adjei A, LoRusso P, Ribas A, Sosman J, Pavlick A, Dy G, et al. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017;35:47-58 pubmed publisher
    ..Limited antitumor activity was demonstrated. Further investigation is not currently planned. ..